Treatment with other HDAC inhibitors, such as API-D, a Class I HDAC inhibitor, also reduced cardiac hypertrophy and transition to heart failure in mice with thoracic aorta constriction, with significantly improved echocardiographic and hemodynamic parameters [43]. Here, HDAC9 is linked to cardiac hypertrophy.